S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.73 -0.02% GOLD 4,016.90 +0.10% CRUDE 83.63 +1.38%
Next Bullish Trade
Sign in
TVTX

Travere Therapeutics, Inc. TVTX

$56.71 +1.43 (+2.59%)
Neutral · +0.45σ

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · TVTX

Momentum reads · latest daily bar
Last
$56.71
+1.43 (+2.59%)
Mkt cap
$5.3B
Healthcare
RSI(14)
58.2
neutral
Stochastic %K
41.2
neutral
MFI(14)
38.7
neutral
ADX(14)
32.5
trending

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $0.1B $-0.0B $-0.0B $-0.1B -29.2% -29.0%
2025-12-31 $0.1B $0.0B $-0.0B $0.0B 2.1% -25.0%
2025-09-30 $0.2B $0.0B $0.0B $-0.0B 15.6% 15.1%
2025-06-30 $0.1B $-0.0B $-0.0B $-0.0B -11.1% -11.1%
2025-03-31 $0.1B $-0.0B $-0.0B $-0.1B -50.4% -52.2%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare TVTX vs peers

Line TVTX up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing TVTX no peers yet — add up to 4 below

Add tickers to compare with TVTX

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-05-04 0.05 -0.06 +187.0% -0.2%
2026-02-19 0.37 0.37 -0.8% +3.7%
2025-10-30 0.59 -0.08 +794.1% +18.6%
2025-08-06 0.13 0.04 +225.0% -1.9%
2025-05-01 -0.19 -0.39 +51.8% +1.9%
2025-02-20 -0.47 -0.38 -24.1% -6.8%
2024-10-31 -0.46 -0.54 +14.3% +0.4%
2024-08-01 -0.65 -0.72 +9.2% -2.6%
2024-05-06 -1.51 -0.79 -90.6% +3.0%
2024-02-15 -0.94 -0.92 -2.0% -6.2%
2023-11-07 2.27 0.04 +5413.7% -11.8%
2023-08-03 -0.77 -0.93 +17.0% -4.7%
2023-05-04 -0.82 -1.03 +20.1% +5.2%
2023-02-23 -0.76 -0.84 +9.2% +1.9%
2022-10-27 -0.76 -0.70 -7.9% +2.0%
2022-08-04 -0.65 -0.70 +6.9% +7.9%
2022-05-05 -0.82 -0.73 -12.5% -9.6%
2022-02-24 -0.61 -0.50 -22.1% -1.1%
2021-10-28 -0.13 -0.48 +73.1% +8.3%
2021-07-29 -0.39 -0.50 +22.0% -0.7%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
TVTX $5B 11.7 9.8 331.7 53.1 55.9% 55.6% -0.97%
LLY $1,051B 41.8 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 17.7 4.0 19.5% 0.4% 61.5% 5.88%
JNJ $609B 29.3 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0%
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.2 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 60.03%

HolderShares% out
Janus Henderson Group PLC 11,419,586 12.28%
FMR, LLC 10,967,967 11.79%
Blackrock Inc. 7,792,033 8.38%
State Street Corporation 4,959,988 5.33%
Armistice Capital, LLC 4,897,417 5.27%
Perceptive Advisors Llc 4,142,551 4.45%
Vanguard Capital Management LLC 4,045,812 4.35%
Nomura Asset Management Internationa 3,270,513 3.52%
Geode Capital Management, LLC 2,369,559 2.55%
Renaissance Technologies, LLC 1,966,779 2.11%

Insider activity · 90d

8 buys / 2 sells · ratio 4.0 · Finnhub

  • Inrig Jula G 112,770
  • Baynes Roy D. M 0
  • Baynes Roy D. SELL 41,500 @ $50.00
  • Baynes Roy D. M 46,000 @ $21.38
  • Coughlin Timothy M 0
  • Coughlin Timothy SELL 56,250 @ $50.07
  • Coughlin Timothy M 66,250 @ $26.52
  • Baynes Roy D. BUY 12,000
  • Baynes Roy D. BUY 41,500
  • Poole Sandra BUY 12,000

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$43.0
Mean
$58.35714
High
$70.0
Analysts
14
Recommendation distribution · period 2026-07-01
8
11
2
Revision trend (2026-04-01 → 2026-07-01): net 18 → 19 +1 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
8-K 2026-07-09 8-K view ·
4 2026-06-22 Insider transaction (Form 4) view ·
4 2026-06-16 Insider transaction (Form 4) view ·
4 2026-06-16 Insider transaction (Form 4) view ·
8-K 2026-06-16 8-K view ·
8-K 2026-06-02 8-K view ·
4 2026-05-21 Insider transaction (Form 4) view ·
4 2026-05-21 Insider transaction (Form 4) view ·
4 2026-05-21 Insider transaction (Form 4) view ·
4 2026-05-21 Insider transaction (Form 4) view ·
4 2026-05-21 Insider transaction (Form 4) view ·
4 2026-05-21 Insider transaction (Form 4) view ·
4 2026-05-21 Insider transaction (Form 4) view ·
4 2026-05-21 Insider transaction (Form 4) view ·
4 2026-05-21 Insider transaction (Form 4) view ·
8-K 2026-05-21 8-K view ·
4 2026-05-19 Insider transaction (Form 4) view ·
8-K 2026-05-11 8-K view ·
4 2026-05-06 Insider transaction (Form 4) view ·
4 2026-05-06 Insider transaction (Form 4) view ·
4 2026-05-06 Insider transaction (Form 4) view ·
4 2026-05-06 Insider transaction (Form 4) view ·
4 2026-05-06 Insider transaction (Form 4) view ·
4 2026-05-06 Insider transaction (Form 4) view ·
4 2026-05-06 Insider transaction (Form 4) view ·
4 2026-05-06 Insider transaction (Form 4) view ·
10-Q 2026-05-04 10-Q view ·
4 2026-05-04 Insider transaction (Form 4) view ·
8-K 2026-05-04 8-K view ·
4 2026-04-23 Insider transaction (Form 4) view ·
4 2026-04-16 Insider transaction (Form 4) view ·
4 2026-04-16 Insider transaction (Form 4) view ·
4 2026-04-16 Insider transaction (Form 4) view ·
4 2026-04-15 Insider transaction (Form 4) view ·
4 2026-04-15 Insider transaction (Form 4) view ·
4 2026-04-15 Insider transaction (Form 4) view ·
4 2026-04-15 Insider transaction (Form 4) view ·
4 2026-04-15 Insider transaction (Form 4) view ·
4 2026-04-15 Insider transaction (Form 4) view ·
8-K 2026-04-14 8-K view ·
4 2026-04-07 Insider transaction (Form 4) view ·
DEF 14A 2026-04-06 DEF 14A view ·
4 2026-04-02 Insider transaction (Form 4) view ·
4 2026-04-02 Insider transaction (Form 4) view ·
4 2026-03-18 Insider transaction (Form 4) view ·
4 2026-02-24 Insider transaction (Form 4) view ·
10-K 2026-02-19 10-K view ·
4 2026-02-19 Insider transaction (Form 4) view ·
8-K 2026-02-19 8-K view ·
4 2026-02-05 Insider transaction (Form 4) view ·
4 2026-02-05 Insider transaction (Form 4) view ·
4 2026-02-05 Insider transaction (Form 4) view ·
4 2026-02-03 Insider transaction (Form 4) view ·
4 2026-02-03 Insider transaction (Form 4) view ·
4 2026-02-03 Insider transaction (Form 4) view ·
4 2026-02-03 Insider transaction (Form 4) view ·
4 2026-02-03 Insider transaction (Form 4) view ·
4 2026-02-03 Insider transaction (Form 4) view ·
4 2026-02-03 Insider transaction (Form 4) view ·
4 2026-01-27 Insider transaction (Form 4) view ·

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics…

Options picks · TVTX

ITM + OTM ideas from the latest scan

Loading…

Congress trades · TVTX

STOCK Act disclosures

Loading…

SEC filings & insiders · TVTX

EDGAR · live

Loading…

Holders · TVTX

Institutions & insider activity

Loading…